Yuhan said in a regulatory filing Tuesday that its consolidated operating profit for last year rose 90.2% from a year earlier to 104.4 billion won.
Revenue increased 5.7% to 2.1866 trillion won, and net profit surged 235.9% to 185.3 billion won, it said in preliminary results.
The company said growth in its prescription-drug business, overseas operations and sales at subsidiaries drove the revenue gain. It said operating profit jumped as it improved its profit structure by raising the share of product sales and lowering its cost ratio. Net profit reflected factors including higher gains from selling investment shares in affiliated companies.
In the fourth quarter, Yuhan said its core pharmaceutical business maintained solid growth, and it booked milestone payments tied to the commercialization in China of a combination therapy using its non-small cell lung cancer drug Lazertinib. As a result, on a separate basis, fourth-quarter revenue rose 53.5 billion won and operating profit increased 31.8 billion won from a year earlier.
A Yuhan official said the company will continue to prioritize profitability, boost research and development productivity, and strengthen disciplined management.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.